Expression of Fatty Acid Synthase Depends on NAC1 and Is Associated with Recurrent Ovarian Serous Carcinomas
Open Access
- 1 January 2010
- journal article
- research article
- Published by Wiley in Journal of Oncology
- Vol. 2010, 1-12
Abstract
Our previous reports demonstrated that NAC1, a BTB/POZ domain-containing nuclear protein, upregulates in recurrent ovarian serous carcinoma and participates in developing drug resistance in cancer cells. The current study applies quantitative proteomics to identify the proteins controlled by NAC1 by comparing the proteomes of SKOV3 cells with and without expression of a dominant negative NAC1 construct, N130. From the proteins that are downregulated by N130 (upregulated by NAC1), we chose to further characterize fatty acid synthase (FASN). Similar to change in protein level, the FASN transcript level in SKOV3 cells was significantly reduced by N130 induction or by NAC1 knockdown. Immunohistochemistry showed that NAC1 and FASN immunointensities in ovarian serous carcinoma tissues had a highly significant correlation (). Moreover, we found that recurrent serous carcinomas exhibited higher FASN immunointensities than their matched primary tumors (). Multivariate analysis showed that an FASN staining score of >1 in serous carcinomas was associated with a worse overall survival time (). Finally, C93, a new FASN inhibitor, induced massive apoptosis in carboplatin/paclitaxel resistant ovarian cancer cells. In conclusion, we show that NAC1 is essential for FASN expression in ovarian serous carcinomas and the expression of FASN significantly correlates with tumor recurrence and disease aggressiveness. The dependence of drug resistant tumor cells on FASN suggests a potential application of FASN-based therapeutics for recurrent ovarian cancer patients.
Keywords
Funding Information
- National Cancer Institute (RO1CA103937)
- HERA Women’s Cancer Foundation (RO1CA103937)
- Entertainment Industry Foundation (RO1CA103937)
This publication has 57 references indexed in Scilit:
- KLF5 enhances SREBP-1 action in androgen-dependent induction of fatty acid synthase in prostate cancer cellsBiochemical Journal, 2008
- Role of microRNAs in drug-resistant ovarian cancer cellsGynecologic Oncology, 2008
- Reversal of Drug Resistance in Ovarian Cancer: Where Do We Go From Here?Journal of Clinical Oncology, 2008
- Annexin XI Is Associated with Cisplatin Resistance and Related to Tumor Recurrence in Ovarian Cancer PatientsClinical Cancer Research, 2007
- Expression and clinical role of the bric-a-brac tramtrack broad complex/poxvirus and zinc protein NAC-1 in ovarian carcinoma effusionsHuman Pathology, 2007
- NAC1, a cocaine‐regulated POZ/BTB protein interacts with CoRESTJournal of Neurochemistry, 2007
- A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survivalProceedings of the National Academy of Sciences, 2006
- Fatty Acid Synthase and Cancer: New Application of an Old PathwayCancer Research, 2006
- Empirical Statistical Model To Estimate the Accuracy of Peptide Identifications Made by MS/MS and Database SearchAnalytical Chemistry, 2002
- The impact of p53 status on cellular sensitivity to antifolate drugs.2001